💡 Inbiomotion: test per predir metàstasis òssia en càncer de mama.
💡 LoopDX: diagnòstic ràpid de sèpsia a UCI.
💡 MAP-AD Test: predicció precoç de l’Alzheimer amb IA.
💡 Mediktor: assistent d’IA per orientar pacients al nivell assistencial adequat.

🧪 Top Spanish hospitals adopt the MAF Test® to transform #BreastCancer care.
#IRBBarcelona + ICREA spin-off #Inbiomotion launches the test in selected hospitals in Barcelona & Madrid—marking a step forward in personalized treatment.

Video credits: Telenotícies 3Cat

#CancerResearch #Innovation

🧪 Inbiomotion, spin-off del IRB ha desarrollado MAF Test, una prueba diagnóstica que, en tan solo 36 horas, es capaz de ayudar a determinar al oncólogo el tratamiento más adecuado en pacientes de cáncer de mama.

✍️ Ainara Valadez

🗞️ ¡Buenos días! Os compartimos nuestra portada de hoy

👉 Inbiomotion introduce su test en hospitales para anticiparse a posibles metástasis del cáncer de mama (✍️ Ainara Valadez)
👉El gigante surcoreano Naver compra Wallapop (✍️ Anna Badia)
👉The Barcelonian: Perdona… ¿puedo entrar en mi casa?

Top Spanish hospitals adopt the MAF Test, developed by @irbbarcelona.org #spinoff #InBioMotion, to improve #BreastCancer treatment

MAF helps determine which patients should be treated with bisphosphonates, improving prognosis & survival #BISTCommunity #PersonalisedMedicine

bist.eu/top-spanish-...

#PortfolioNews I MAF Test® now adopted in top #Spanish hospitals to personalize early-stage #breast #cancer treatment. A major step for our #portfolio company #Inbiomotion !

👉 Full details here - buff.ly/aT4nwud

#BreastCancer #Oncology #PortfolioNews #MAFTest

🧪Top Spanish hospitals adopt the MAF Test, by #IRBBarcelona spinoff #Inbiomotion, to improve breast cancer treatment. This test helps oncologists determine which #BreastCancer patients should be treated with bisphosphonates to improve their prognosis & survival.

➡️ shorturl.at/AbzSI

🎥 Credit: 3Cat

🔬 Un nou test de pronòstic per al càncer de mama arriba als hospitals catalans
 
Un conjunt de centres públics i privats de Barcelona i Madrid, han estat els primers a incorporar el MAF Test®, desenvolupat per la biotech catalana Inbiomotion.

La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales

🧪Top Spanish hospitals adopt the MAF Test to improve breast cancer treatment. This pioneering test by #IRBBarcelona spinoff #Inbiomotion helps oncologists determine which #BreastCancer patients should be treated with bisphosphonates to improve their prognosis & survival.

➡️ https://shorturl.at/AbzSI

La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales

🧪Don't miss this webinar by Dr. @rgergom.bsky.social (#IRBBarcelona-#Inbiomotion) that explores the biology & mechanism of action of the MAF gene, shedding light on its significant impact on patient outcomes.

@sourcebioscience.bsky.social

https://youtu.be/M7bvPjPQCq0?feature=shared

#BreastCancer